Sanofi shares new data for long-term efficacy of Nexviazyme for Pompe disease treatment

Betsy Goodfellow | October 6, 2023 | News story | Research and Development Nexviazyme, Pharmacy, Pompe disease, Sanofi 

Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the treatment of Pompe disease at the 28th Annual Congress of the World Muscle Society (WMS) in Charleston, South Carolina, US.

Nexviazyme is approved in the US and elsewhere as a monotherqapy for the treatment of late-onset Pompe disease, and is approved for infantile-onset Pompe disease in Europe and other countries. The drug is currently in a phase 3 trial for infantile-onset Pompe disease in the US.

The data shared included results from the phase 3 COMET trial evaluating the long-term efficacy, safety and durability of the drug in patients with late-onset Pompe disease, with the nearly three-year data showing that patients on the drug had improvement or stabilisation of respiratory function and mobility. The data also showed that the drug was well-tolerated by patients who had previously been treated with alglucosidase alfa.

Advertisement

Alaa Hamed, MD MPH MBA, global head of medical affairs for Rare Diseases at Sanofi, commented: “Our findings being shared at WMS build upon existing evidence that supports the value of Nexviazyme in treating Pompe disease. With efficacy and safety demonstrated across a variety of patient cohorts, we remain confident in Nexviazyme as a compelling treatment option.”

Betsy Goodfellow

Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria

Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition

The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

sanofi

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline

Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …

The Gateway to Local Adoption Series

Latest content